Safety Information

Last updated: September 2025

IMPORTANT NOTICE

This information pertains to both FDA-approved medications and compounded formulations. Medberri offers FDA-approved branded medications (such as Zepbound® and Ozempic®) and, when medically appropriate, compounded formulations. Compounded medications have not been evaluated by the FDA for safety, effectiveness, or quality.

Zepbound® and Mounjaro® are registered trademarks of Eli Lilly. Ozempic® and Wegovy® are registered trademarks of Novo Nordisk. Medberri has no affiliation with Eli Lilly or Novo Nordisk. When we dispense these branded medications, they are the actual FDA- approved products manufactured by these companies.

Educational Information: Understanding GLP-1 and GIP Receptor Medications

GLP-1 receptor agonist medications work by mimicking the action of the GLP-1 hormone in your body. This hormone helps regulate appetite, reduce hunger, and increase feelings of fullness. Some medications may target both GLP-1 and GIP receptors, which can help regulate different aspects of metabolism and appetite.

When used as part of a comprehensive program that includes diet and exercise, these medications may support weight management efforts. Individual results vary, and weight management is influenced by multiple factors including diet, exercise, consistency with treatment, and individual biological factors.

FDA-APPROVED BRANDED MEDICATIONS SAFETY INFORMATION

Zepbound® Safety Information

Important Safety Information for Zepbound® injection
Warning: Risk of Thyroid C-Cell Tumors

In rats, Zepbound® caused thyroid tumors, including thyroid cancer. It is not known ifZepbound® will cause thyroid tumors or a type of thyroid cancer called medullarythyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling inyour neck, hoarseness, trouble swallowing, or shortness of breath. These may besymptoms of thyroid cancer.

Do not use Zepbound® if you or any of your family have ever had a type of thyroid cancercalled medullary thyroid carcinoma (MTC) or if you have an endocrine system conditioncalled Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

What is the FDA-approved use of Zepbound®?

Zepbound® is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

  • 30 kg/m2 or greater (obesity)
  • 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease)

Individual results may vary, and no specific amount of weight management can be guaranteed.

Limitations of use:

  • Zepbound® should not be used in combination with other products containing the same active ingredient or any other GLP-1 receptor agonist.
  • The safety and efficacy of coadministration with other products for weight management have not been established.
  • Zepbound® has not been studied in patients with a history of pancreatitis.

Who should not use Zepbound®?

Do not use Zepbound® if:

  • You or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • You have a known allergic reaction to Zepbound®.

How should I take Zepbound®?

You can take Zepbound® with or without food. The pre-filled injector pen is self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week. Your Medberri provider will guide you on a treatment regimen that may include an increase in dose every four weeks.

You should not change your dosing regimen or stop taking Zepbound® as prescribed without discussing with your provider first.

What should I tell my Medberri provider before using Zepbound®?

Zepbound® has certain drug interactions. It’s important to tell your Medberri provider all of the medications you are currently taking, including prescription, over-the-counter medications, vitamins, and herbal and dietary supplements.

Some medications to watch out for include:

  • Medications for diabetes: Medications used to treat type 1 or type 2 diabetes, including insulin or sulfonylureas (such as Amaryl or Glucotrol XL)
  • Other oral medications: Zepbound® causes a delay in gastric emptying, so it has the potential to impact the absorption of medications that are taken by mouth at the same time. Your provider can guide you on how to schedule your medications.
  • Hormonal birth control: If you are using an oral hormonal contraceptive (birth control), Zepbound® may decrease its efficacy, especially after the first dose. Switch to a non-oral contraceptive method or use a barrier method of contraception for 4 weeks after starting Zepbound® and for 4 weeks after each dose escalation, until you reach a maintenance dose.
  • Other GLP-1 medications: including Wegovy® (semaglutide), Ozempic® (semaglutide), Saxenda® (liraglutide), Mounjaro® (same active ingredient as Zepbound®), Victoza® (liraglutide), Byetta® (exenatide), or Bydureon® (exenatide).
  • Other products for weight management: Including dietary supplements

It’s important to share your entire medical history with your provider. In particular, tell your provider if you have a past history of:

  • Type 1 or type 2 diabetes
  • Thyroid cancer
  • Gastrointestinal disease
  • Pancreatitis
  • Kidney disease
  • Diabetic retinopathy
  • Depression
  • Suicidal thoughts or behavior

Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding.

  • If you are pregnant: Zepbound® should not be used during pregnancy. Based on animal studies, there may be potential risks to an unborn baby from exposure to Zepbound® during pregnancy. There is no benefit to weight management during pregnancy and it may cause harm to the unborn baby.
  • If you are of reproductive potential: Zepbound® may reduce the efficacy of oral hormonal contraceptives. Switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after starting medication and for 4 weeks after each dose escalation until you reach a maintenance dose.
  • If you are breastfeeding: It is not known if Zepbound® passes into breast milk. Talk to your provider first about the benefits and risks of using Zepbound® while breastfeeding.

Pregnancy registry: There is a pregnancy exposure registry that monitors pregnancyoutcomes in women exposed to Zepbound® during pregnancy. Pregnant patientsexposed to Zepbound® and healthcare providers are encouraged to contact Eli Lilly andCompany at 1-800-LillyRx (1-800-545-5979).

Withholding or providing inaccurate information about your health and medical historyin order to obtain treatment may result in harm, including, in some cases, death.

What are the most serious side effects that I or a caregiver should monitor for when taking Zepbound®?

If you are experiencing a medical emergency, call 911 or seek immediate medical attention.

These serious side effects are rare, but can occur with Zepbound®. You or a caregiver should carefully monitor for these side effects, especially in the beginning of treatment and with dose changes.

  • Thyroid C-Cell Tumors: In rats, Zepbound® caused a dose-dependent and treatment-duration-dependent increase in thyroid C-cell tumors. It is unknown whether Zepbound® causes thyroid C-cell tumors in humans. Zepbound® is contraindicated in patients with a family history of medullary thyroid cancer (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
  • Severe Gastrointestinal Disease: Zepbound® is associated with gastrointestinal side effects, such as nausea, diarrhea, vomiting, constipation, and stomach pain, and can sometimes be severe. It hasn’t been studied in patients with severe gastrointestinal disease and isn’t recommended in these patients. The majority of nausea, vomiting, and/or diarrhea events occurred during a dose increase and decreased over time.
  • Acute Kidney Injury: Gastrointestinal side effects of Zepbound® like diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems if dehydration is severe. It is important for you to drink plenty of water to help reduce your chance of dehydration.
  • Acute Gallbladder Disease: Zepbound®, other GLP-1 receptor agonists, and weight management are associated with an increased chance of acute gallbladder disease. Tell your provider right away if you have pain in your upper stomach, yellowing of skin or eyes (jaundice), fever, or clay-colored stools.
  • Inflammation of Pancreas (Acute Pancreatitis): Monitor for signs of acute pancreatitis, including severe abdominal pain that does not go away, sometimes radiating to the back, with or without vomiting.
  • Allergic Reactions: Stop using Zepbound® right away if you experience symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, severe rash or itching, very rapid heartbeat, problems breathing or swallowing, or fainting or feeling dizzy.
  • Low Blood Sugar (Hypoglycemia): Zepbound® lowers blood glucose. It can cause too low blood sugar in patients with type 2 diabetes who also take another glucose control medication. Monitor your blood sugar and watch out for signs of too low blood sugar such as dizziness, blurred vision, mood changes, sweating, or fast heartbeat.
  • Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Rapid improvement of glucose control has been associated with temporary worsening of diabetic retinopathy. Tell your provider right away if you experience changes in vision.
  • Suicidal Behavior and Ideation: You should pay attention to any mental health changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you.
  • Never Share a Pen: Pen-sharing poses a risk of infection.

What are the most common side effects of Zepbound®?

  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Stomach pain
  • Indigestion
  • Injection site reactions
  • Feeling tired
  • Allergic reactions
  • Belching
  • Hair loss
  • Gastroesophageal reflux disease (heartburn)

You are encouraged to report negative side effects of prescription products to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

This information is not comprehensive. Please see the full Prescribing Information for complete safety information.

Ozempic® and Wegovy® (Semaglutide) Safety Information

Warning: Risk of Thyroid C-Cell Tumors

  • In studies with mice and rats, semaglutide (the active ingredient in Wegovy® and Ozempic®) caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® or Ozempic® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer.
  • Do not use Wegovy® or Ozempic® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

What is the FDA-approved use of Wegovy®?

Wegovy® is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:

  • 30 kg/m² or greater (obesity) or
  • 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).

Individual results may vary, and no specific amount of weight management can be guaranteed.

What is the FDA-approved use of Ozempic®?

Ozempic® is used:

  • Along with diet and exercise to improve blood sugar in adults with type 2 diabetes.
  • To reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.

Ozempic® is not approved for weight management, though weight management may occur while using it.

Common side effects of semaglutide medications may include:

  • Nausea
  • Diarrhea
  • Vomiting
  • Stomach pain
  • Constipation
  • Headache
  • Fatigue
  • Dizziness
  • Abdominal pain
  • Decreased appetite
  • Indigestion
  • Flatulence
  • Gastroesophageal reflux disease
  • Hypoglycemia in patients with type 2 diabetes

Individual experiences vary, and not all patients experience the same side effects.

You are encouraged to report negative side effects of prescription products to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

This information is not comprehensive. Please see the full Prescribing Information for Wegovy® or Prescribing Information for Ozempic® for complete safety information.

COMPOUNDED MEDICATION INFORMATION

Important Information About Compounded GLP-1 and Dual GLP-1/GIP Receptor Agonist Medications

Medberri may, when medically appropriate, offer compounded formulations of medications that target GLP-1 receptors or both GLP-1 and GIP receptors. These compounded medications are different from FDA-approved branded products like Ozempic®, Wegovy®, and Zepbound®.

What are compounded medications?

Compounded medications are custom-prepared by licensed pharmacies to meet specific patient needs when commercially available options aren’t suitable. They are made by combining, mixing, or altering ingredients to create a medication tailored to individual patient requirements as determined by a licensed healthcare provider.

Important regulatory information:

  • Compounded medications have NOT been evaluated by the FDA for safety, effectiveness, or quality.
  • Compounded medications do not undergo the same rigorous clinical trials as FDA-approved medications.
  • The FDA does not verify the safety, effectiveness, or quality of compounded medications.
  • Compounded medications may contain the same active ingredients as FDA-approved medications but may differ in formulation, strength, and quality.

Potential risks of compounded medications:

  • Quality, potency, and purity may vary between compounding pharmacies.
  • May contain different inactive ingredients than FDA-approved versions.
  • May have different side effects or risks than FDA-approved versions.
  • Limited data on long-term safety and effectiveness.

When might compounded medications be appropriate?

  • When FDA-approved medications are unavailable due to shortages.
  • When a patient has a documented allergy to an inactive ingredient in the FDA-approved version.
  • When a patient requires a specific dosage form not commercially available.
  • When determined medically necessary by your healthcare provider.

Safety monitoring for compounded medications:

  • All side effects should be reported to your Medberri provider immediately.
  • Your provider will monitor your response to treatment closely.
  • Follow all instructions provided by your healthcare provider regarding dosage and administration.

Informed consent:

Before receiving any compounded medication, you will be asked to provide informed consent acknowledging that you understand the differences between FDA-approved and compounded medications.

Disclaimer

Ozempic®, Wegovy®, Saxenda®, and Victoza® are registered trademarks of Novo Nordisk. Zepbound®, Mounjaro®, are registered trademarks of Eli Lilly. Medberri has no affiliation with Novo Nordisk or Eli Lilly. The compounded products available as part of Medberri’s Weight Management Program are not made by Novo Nordisk or Eli Lilly or any company affiliated with Novo Nordisk or Eli Lilly.